• CFTRinh-172: Evidence, Uses, and Limitations

  2026-10-08

  CFTRinh-172 is a preclinical small-molecule inhibitor used to interrogate CFTR-dependent chloride transport. This overview separates supplier-reported pharmacology from peer-reviewed findings, explains its conceptual relevance to cystic fibrosis research and secretory diarrhea models, and compares channel inhibition with CFTR trafficking studies while emphasizing evidence gaps, model dependence, and translational boundaries.

• Nanoparticle Uptake in Human Corneal Cells

  2026-10-08

  Azadi and David examined how nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells, using PLGA particles with alginate, chitosan, or PEG surface modifications. Their results identify energy-dependent uptake, with macropinocytosis and caveolae-associated endocytosis contributing most strongly under the tested conditions, while also defining important limits for translating this in vitro evidence to ocular therapy.

• 4-Hydroxytamoxifen B6167 Product Overview

  2026-10-07

  4-Hydroxytamoxifen (SKU B6167) is cataloged by APExBIO as an estrogen receptor modulator. This overview covers supplier-reported identity and conceptual research scope only; no matched paper evidence is available for independent efficacy or mechanism claims.

• CBEmax mRNA: Evidence, Applications, and Limits

  2026-10-07

  Cytosine base editing is a promising approach for studying single-nucleotide changes, but editor fidelity is context-dependent. A family-based whole-genome study in mouse embryos found excess single-nucleotide variants and deletions with BE4, whereas ABE showed substantially fewer unintended changes. These findings inform how researchers should interpret cytosine base-editor studies, but they do not establish the performance of R1044 EZ Cap™ CBEmax mRNA (m1Ψ), which was not evaluated in the cited paper.

• VX-661 and the Logic of F508del CFTR Rescue

  2026-10-06

  VX-661, a F508del CFTR corrector, is best understood through the interaction of protein folding, calnexin-dependent proteostasis, and functional channel rescue. This article explains how recent deep mutational scanning reshapes interpretation in cystic fibrosis research without reducing response to a single assay endpoint.

• Nystatin (Fungicidin): Evidence and Research Context

  2026-10-06

  Nystatin, also known as Fungicidin, is a polyene antifungal whose research importance comes from its interaction with ergosterol-containing fungal membranes. This overview separates supplier-reported activity against Candida and Aspergillus from the directly published ocular nanoparticle study supplied, and assesses what those findings can—and cannot—support across antifungal, adhesion, and drug-delivery research.

• How S. eriocheiris Enters Drosophila S2 Cells

  2026-10-05

  Wei and colleagues established a Drosophila Schneider 2-cell model showing that Spiroplasma eriocheiris can enter insect-derived cells, proliferate intracellularly, and trigger substantial cellular injury. Pharmacological and cytoskeletal evidence implicated clathrin-mediated endocytosis and macropinocytosis, while the findings did not support a major role for caveola-associated cholesterol-dependent entry.

• From RNA Tailing to Local Translation Insight

  2026-10-05

  Poly(A) tailing is more than a finishing step in in vitro transcription RNA modification. This thought-leadership article connects RNA quality, translation control, and spatial biology, using recent endosome-associated lc3b research to define where the HyperScribe™ Poly (A) Tailing Kit fits—and where evidence must still be generated.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-10-04

  A 2025 bioRxiv preprint evaluates Shufeng Xingbi Therapy in an ovalbumin-associated rat model of allergic rhinitis using behavioral, histological, immune, molecular, microbiome, and short-chain fatty acid measurements. The findings support a microbiome–immune association, but the preprint’s small animal sample, combined treatment groups, and lack of peer review limit causal and clinical interpretation.

• Removing Pollen Interference in EEM Bioaerosol Detection

  2026-10-03

  Zhang et al. examined how pollen fluorescence can confound the classification of bacterial and toxin-related bioaerosol samples using excitation–emission matrix spectroscopy. Their central contribution was a data-processing and machine-learning framework in which fast Fourier transform features improved reported classification accuracy to 89.24%, although the findings remain limited to the study dataset and require external validation.

• Polymyxin B Sulfate: MDR Research Workflows

  2026-10-02

  Polymyxin B sulfate supports practical workflows spanning Gram-negative susceptibility testing, resistant-infection models, and immune-response assays. This guide connects membrane-disruption biology with plasmid-transmission findings and provides executable setup parameters plus troubleshooting safeguards.

• Olive Oil Polyphenols and Cardiovascular Protection

  2026-10-01

  The 2025 reference study compares standard and naturally high-phenolic extra virgin olive oil extracts with hydroxytyrosol and tyrosol across redox, inflammatory, and cholesterol-efflux assays. Its central contribution is showing that polyphenol concentration and molecular composition shape antioxidant, anti-inflammatory, and anti-atherogenic responses, while also defining practical in vitro endpoints for cardiovascular health research.

• Nystatin (Fungicidin): Assay Workflows

  2026-10-01

  Nystatin (Fungicidin) combines a defined ergosterol-targeting mechanism with practical workflows for Candida susceptibility, adhesion, formulation, and infection-model controls. Its lack of effect on Spiroplasma entry in S2 cells also makes it a useful negative comparator when separating fungal membrane biology from endocytic mechanisms.

• Sodium Pyruvate in Cell Culture: A Decision Guide

  2026-09-30

  Sodium pyruvate is more than a routine media additive: it can alter carbon flux, redox balance, and stress phenotypes in cultured cells. This guide connects mechanism-based assay design with a 2025 rabbit pharming study to clarify what metabolic supplementation can—and cannot—tell you.

• Nystatin (Fungicidin) Research Workflows

  2026-09-30

  Build reproducible Candida, adhesion, and membrane-disruption assays with Nystatin (Fungicidin), while using nanoparticle uptake principles to inform exploratory delivery studies. This research-focused guide combines practical stock preparation, dose-response design, controls, and troubleshooting for antifungal workflows.

8433 records 1/563 page Next 12345 下5页 Last page